Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference
Absci (Nasdaq: ABSI) will participate in the 25th Annual Needham Virtual Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Absci (Nasdaq: ABSI) will participate in the 25th Annual Needham Virtual Healthcare Conference.
Management is scheduled for a fireside chat on April 16, 2026 at 1:30 p.m. ET (10:30 a.m. PT). A live and archived webcast will be available on the company's investor relations website.
Details
News Market Reaction – ABSI
On Apr 8, the day this news came out, ABSI closed 2.40% above the previous close.
Data tracked by StockTitan Argus for the Apr 8 session.
Key Figures
- Conference edition
- 25th Annual
- Needham Virtual Healthcare Conference
- Fireside chat time
- 1:30 p.m. ET
- Scheduled on Thursday, April 16th
Historical Context
-
Q4 and 2025 results plus ABS-201 safety and cash runway update.
-
Endometriosis Advisory Board formed to guide ABS-201 Phase 2 plans.
-
Inducement stock option grant to new Chief Medical Officer.
-
New CMO appointed and Chief Innovation Officer transition announced.
-
Announcement of timing for Q4 and full-year 2025 results call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
VANCOUVER, Wash. and NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will be participating in the upcoming 25th Annual Needham Virtual Healthcare Conference.
Absci management is scheduled to participate in a fireside chat on Thursday, April 16th at 1:30 p.m. Eastern Time (10:30 a.m. Pacific Time). Interested parties may access a live and archived webcast on the company’s investor relations website at: investors.absci.com.
About Absci
Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics including ABS-201™, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern hair-loss. ABS-201 is also being investigated as a potential “best-in-class” therapeutic for endometriosis, a condition with significant unmet medical need and market potential. Absci is headquartered in Vancouver, WA, with AI Research Labs in New York City and Serbia, and an Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn (@absci), X (@Abscibio) and YouTube.
Absci® standard character mark, ABS-201™, and Integrated Drug Creation™ are trademarks and registered trademarks of Absci Corporation.
Investor Contact
Alexander D.H. Khan
Corporate Vice President
Head of Investor Relations
investors@absci.com
Media Contact
press@absci.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.